

BCBSMT HEDIS® 2014 COMPARISON REPORT - Managed Care

EFFECTIVENESS OF CARE MEASURES

	BCBSMT 2012		BCBSMT 2013			BCBSMT 2014			2013 QC National	2014 QC National
	Num	Denom	Num	Denom	% change			% change		
Childhood Immunization	n=51		n=31			n=16				
DTaP	43	51	26	31	-0.52%	14	16	4.33%	87.20%	86.70%
Hib	46	51	30	31	7.29%	15	16	-3.13%	94.30%	93.50%
IPV	45	51	30	31	9.67%	16	16	3.33%	92.80%	92.20%
PCV	43	51	27	31	3.31%	15	16	7.64%	86.70%	87.00%
HepB	45	51	30	31	9.67%	16	16	3.33%	89.20%	88.10%
MMR	48	51	29	31	-0.61%	16	16	6.90%	91.80%	91.50%
VZV	44	51	29	31	8.44%	16	16	6.90%	91.60%	91.50%
HepA^	21	51	28	31	119.34%	16	16	10.71%	65.50%	82.50%
Rotavirus	39	51	21	31	-11.41%	16	16	47.62%	76.70%	79.90%
Influenza	25	51	20	31	31.61%	11	16	6.56%	63.30%	65.30%
Combo-1	41	51	25	31	0.32%	13	16	0.75%	na	na
Combo-2	39	51	25	31	5.46%	13	16	0.75%	79.70%	78.80%
Combo-3	38	51	25	31	8.23%	13	16	0.75%	76.80%	76.60%
Combo-4 ^	16	51	23	31	136.51%	13	16	9.51%	na	na
Combo-5	34	51	18	31	-12.91%	13	16	39.93%	na	na
Combo-6	22	51	17	31	27.12%	8	16	-8.82%	na	na
Combo-7 ^	15	51	17	31	86.46%	13	16	48.16%	na	na
Combo-8 ^	10	51	16	31	163.20%	8	16	-3.13%	na	na
Combo-9	21	51	12	31	-6.00%	8	16	29.17%	na	na
Combo-10 ^	10	51	11	31	80.95%	8	16	40.91%	37.90%	49.30%
Adolescent Immunizations	n=65		n=55			n=42				
Meningococcal (MCV)	39	65	30	55	-7.58%	25	42	7.35%	66.00%	69.50%
Tdap/Td	54	65	44	55	-3.71%	36	42	7.14%	79.20%	81.50%
Combo-1	38	65	29	55	-9.80%	25	42	12.88%	63.70%	67.50%
HPV Vaccine for Female Adolescents	n=28		n=31			n=3				
	8	28	6	31	-32.25%	3	23	-32.61%	na	14.20%
Appropriate Tx for Children w/ URI	n=114		n=53			n=60				
	93	114	44	53	1.76%	49	60	-1.63%	84.00%	85.20%
Appropriate Testing for Children w/ Pharyngitis	n=116		n=52			n=31				
	89	116	32	52	-19.79%	19	31	-0.40%	80.20%	80.70%
Avoidance of Antibiotic Tx for Adults w/ Acute Bronchitis	n=70		n=66			n=46				
	7	70	11	66	66.70%	8	46	4.33%	24.60%	26.10%
Colorectal Cancer Screening	n=601		n=1153			n=702				
	303	601	657	1153	13.01%	393	702	-1.75%	63.30%	63.30%

EFFECTIVENESS OF CARE MEASURES
BCBSMT 2012
BCBSMT 2013
BCBSMT 2014
2013 QC National
2014 QC National

	Num	Denom		Num	Denom		% change				% change		
Breast Cancer Screening^^			n=486			n=865							
	328	486	67.49%	652	865	75.38%	11.68%	280	347	80.69%	7.05%	70.30%	74.30%
Cervical Cancer Screening^^^			n=644			n=982							
	501	644	77.80%	766	982	78.00%	0.26%	497	615	80.81%	3.60%	75.50%	na
Persistence of Beta Blocker Treatment after Heart Attack			n=2			n=5							
	2	2	100.00%	5	5	100.00%	0.00%	2	2	100.00%	0.00%	83.90%	83.90%
Controlling High Blood Pressure			n=na			n=na							
Blood Pressure < 140/90 mmHg	na	na	na	na	na	na	na	121	180	67.22%		63.00%	64.40%
Cholesterol Management for Patients w/ Cardiovascular Conditions			n=26			n=37							
LDL-screening	24	26	92.31%	35	37	94.59%	2.47%	20	22	90.91%	-3.90%	88.30%	86.70%
Comprehensive Diabetes Care			n=82			n=152							
HbA1c Tested	75	82	91.46%	146	152	96.05%	5.02%	79	86	91.86%	-4.36%	90.10%	89.90%
Poor HbA1c Control >9.0% *	17	82	20.73%	20	152	13.16%	-36.53%	15	86	17.44%	32.56%	28.50%	30.50%
HbA1c < 8.0%	57	82	69.51%	115	152	75.66%	8.84%	63	86	73.26%	-3.17%	61.30%	58.90%
HbA1c < 7.0% **	29	61	47.54%	56	105	53.33%	12.19%	30	65	46.15%	-13.46%	43.20%	39.80%
Eye Exam	50	82	60.98%	93	152	61.18%	0.33%	43	86	50.00%	-18.28%	56.80%	55.70%
LDL Screening	67	82	81.71%	134	152	88.16%	7.89%	71	86	82.56%	-6.35%	85.40%	84.90%
LDL Level < 130 mg/dL	59	82	71.95%	110	152	72.37%	0.58%	57	86	66.28%	-8.41%	na	na
LDL Level < 100 mg/dL	37	82	45.12%	78	152	51.32%	13.73%	38	86	44.19%	-13.89%	48.40%	46.70%
Nephropathy Monitored	75	82	91.46%	140	152	92.11%	0.71%	77	86	89.53%	-2.79%	84.30%	84.50%
Blood Pressure < 140/80 mmHg	34	82	41.46%	71	152	46.71%	12.66%	44	86	51.16%	9.53%	44.30%	43.00%
Blood Pressure < 140/90 mmHg	63	82	76.83%	111	152	73.03%	-4.95%	64	86	74.42%	1.91%	66.50%	65.00%
Follow-up for Mental Illness			n=11			n=14							
7 days	5	11	45.45%	6	14	42.86%	-5.70%	5	9	55.56%	29.63%	57.90%	54.60%
30 days	9	11	81.82%	11	14	78.57%	-3.97%	6	9	66.67%	-15.15%	76.00%	72.80%
Antidepressant Medication Management			n=50			n=38							
Effective Acute Phase Tx	33	50	66.00%	27	38	71.05%	7.66%	20	32	62.50%	-12.04%	69.10%	64.40%
Effective Continuation Phase TX	23	50	46.00%	21	38	55.26%	20.14%	18	32	56.25%	1.79%	53.60%	47.40%
Follow-Up for Children Prescribed ADHD Medication			n=9			n=20							
Initiation Phase Visit	5	9	55.56%	4	20	20.00%	-64.00%	4	13	30.77%	53.85%	38.60%	39.90%
Continuation Phase	0	0	0.00%	1	5	20.00%	na	0	1	0.00%	na	45.70%	46.80%
Use of Appropriate Medications for People with Asthma***			n=26			n=49							
Ages 5-11	3	4	75.00%	2	3	66.67%	-11.11%	2	2	100.00%	50.00%	95.50%	96.70%

EFFECTIVENESS OF CARE MEASURES

			BCBSMT 2012		BCBSMT 2013				BCBSMT 2014				2013 QC National	2014 QC National
	Num	Denom		Num	Denom	% change				% change				
Ages 12-18	1	1	100.00%	3	4	75.00%	-25.00%	1	1	100.00%	33.33%		92.20%	93.10%
Ages 19-50	11	12	91.67%	17	23	73.91%	-19.37%	7	8	87.50%	18.38%		88.20%	88.60%
Ages 51-64	8	9	88.89%	16	19	84.21%	-5.26%	6	7	85.71%	1.79%		92.40%	92.60%
Combined ***	23	26	88.46%	38	49	77.55%	-12.33%	16	18	88.89%	14.62%		91.20%	91.60%
Medications Management for People with Asthma (75%)			n=23	n=38				n=16						
Ages 5-11	0	3	0.00%	0	2	0.00%	na	1	2	50.00%	na		32.40%	38.40%
Ages 12-18	0	1	0.00%	1	3	33.33%	na	0	1	0.00%	-100.00%		32.00%	35.30%
Ages 19-50	4	11	36.36%	6	17	35.29%	-2.94%	3	7	42.86%	21.43%		39.70%	43.80%
Ages 51-64	6	8	75.00%	9	16	56.25%	-25.00%	4	6	66.67%	18.52%		52.60%	55.60%
Combined	10	23	43.48%	16	38	42.11%	-3.16%	8	16	50.00%	18.75%		41.80%	46.10%
Asthma Medication Ratio			n=na	n=49				n=15						
Ages 5-11	na	na	na	2	3	66.67%	na	2	2	100.00%	50.00%		na	89.40%
Ages 12-18	na	na	na	2	4	50.00%	na	1	1	100.00%	100.00%		na	78.90%
Ages 19-50	na	na	na	12	23	52.17%	na	6	8	75.00%	43.75%		na	73.50%
Ages 51-64	na	na	na	15	19	78.95%	na	6	7	85.71%	8.57%		na	83.00%
Combined	na	na	na	31	49	63.27%	na	15	18	83.33%	31.72%		na	79.70%
Use of Spirometry in the Assessment & Diagnoses of COPD			n=25	n=29				n=10						
	10	25	40.00%	17	29	58.62%	46.55%	7	10	70.00%	19.41%		43.50%	42.50%
Pharmacotherapy Management of COPD Exacerbation			n=6	n=2				n=1						
Bronchodilator	5	6	83.33%	2	2	100.00%	20.00%	1	1	100.00%	0.00%		80.80%	80.10%
Systemic Corticosteroid	5	6	83.33%	2	2	100.00%	20.00%	1	1	100.00%	0.00%		73.50%	75.50%
Chlamydia Screening			n=98	n=135				n=78						
Ages 16-20	14	41	34.15%	17	57	29.82%	-12.67%	11	34	32.35%	8.48%		41.10%	41.10%
Ages 21-24	22	57	38.60%	33	78	42.31%	9.61%	11	44	25.00%	-40.91%		49.20%	50.30%
Combined	36	98	36.73%	50	135	37.04%	0.84%	22	78	28.21%	-23.85%		45.10%	46.20%
Use of Imaging Studies for Low Back Pain			n=78	n=78				n=57						
	59	78	75.64%	58	69	84.06%	11.13%	44	57	77.19%	-8.17%		75.30%	75.20%
DMARD Therapy in Rheumatoid Arthritis			n=9	n=17				n=4						
	8	9	88.89%	15	17	88.24%	-0.74%	4	4	100.00%	13.33%		87.90%	88.10%
Annual Monitoring for Patients on Persistent Medications			n=321	n=591				n=251						
ACE/ARB	146	176	82.95%	286	336	85.12%	2.61%	120	137	87.59%	2.90%		82.90%	83.30%
Anticonvulsant	5	8	62.50%	6	8	75.00%	20.00%	1	4	25.00%	-66.67%		58.80%	59.10%
Digoxin	4	4	100.00%	13	14	92.86%	-7.14%	3	4	75.00%	-19.23%		86.50%	86.50%

EFFECTIVENESS OF CARE MEASURES

BCBSMT 2012

BCBSMT 2013

BCBSMT 2014

2013 QC National

2014 QC National

	Num	Denom		Num	Denom		% change				% change		
Diuretic	108	133	81.20%	198	233	84.98%	4.65%	91	106	85.85%	1.02%	82.50%	82.90%
Combined	263	321	81.93%	503	591	85.11%	3.88%	215	251	85.66%	0.64%	82.30%	82.70%

** Note: For this numerator, a lower rate indicates better performance.*

*** Note: The HbA1c < 7.0% denominator excludes members w/ certain conditions. Please see measure description for a list of conditions.*

****Note: Medical record review was completed on this measures for HEDIS 2012 & 2013, but not HEDIS 2014.*

^Note: The NCQA qualifying dosing requirements for the Hepatitis A immunizations series changed from 2 doses in 2012 to 1 dose in 2013 & 2014.

^^ Note: The Breast Cancer Screening age qualifying range for women changed to women age 50-74 years in 2014 from 40-74 years in 2013 & 2012.

^^^ Note: The Cervical Cancer Screening screening frequency in 2014 changed to allow two screening methods. For women who had cervical cytology/HPV co-testing, the screening frequency is extended to every 5 years. For women with only cervical cytology testing, the screening frequency remains every 3 years.

BCBSMT 2012 rates based on 2011 data.

BCBSMT 2013 rates based on 2012 data.

BCBSMT 2014 rates based on 2013 data.

The 2014 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2014 Report* and reflect 2013 data.

The 2013 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2013 Report* and reflect 2012 data.

